ArticleTherapeutic advances in medical oncology2017
DNM3, p65 and p53 from exosomes represent potential clinical diagnosis markers for glioblastoma multiforme.
Article in Therapeutic advances in medical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 37 citations in OpenAlex.
- Proteomic Analysis of Extracellular Vesicles Reveals Vitronectin and Laminin Subunit Alpha-3 as Candidate Biomarkers for Gastric Cancer.Gut and liver · 2026Article
- A Comparison of the Effects of Vitamin B12 and Folic Acid on Gait Recovery and Myelination After Femoral Nerve Injury in Rats.International journal of molecular sciences · 2026Article
- Past, present, and future of exosomes research in cancer: A bibliometric and visualization analysis.Human vaccines & immunotherapeutics · 2025Article
- Role of exosomes in cancer: from diagnosis to therapy.Discover oncology · 2025Review
- Liquid Biopsy-Derived Tumor Biomarkers for Clinical Applications in Glioblastoma.Biomolecules · 2025Review
- Folic Acid Promotes Peripheral Nerve Injury Repair via Regulating DNM3-AKT Pathway Through Mediating Methionine Cycle Metabolism.Neuromolecular medicine · 2025Article
- Relationship between exosomes and cancer: formation, diagnosis, and treatment.International journal of biological sciences · 2025Review
- Advancing functional foods: a systematic analysis of plant-derived exosome-like nanoparticles and their health-promoting properties.Frontiers in nutrition · 2025Review
- Review
- ELAVL2 loss promotes aggressive mesenchymal transition in glioblastoma.NPJ precision oncology · 2024Article
- Exosomes as Novel Diagnostic Biomarkers and Therapeutic Tools in Gliomas.International journal of molecular sciences · 2023Review
- Therapeutic and Diagnostic Potential of Exosomes as Drug Delivery Systems in Brain Cancer.Pharmaceutics · 2023Review
- Extracellular vesicles: The key for precision medicine in glioblastoma.Neuro-oncology · 2022Article
- The Exosome Journey: From Biogenesis to Regulation and Function in Cancers.Journal of oncology · 2022Review
- The biology, function, and applications of exosomes in cancer.Acta pharmaceutica Sinica. B · 2021Review
- Lysine demethylase LSD1 delivered via small extracellular vesicles promotes gastric cancer cell stemness.EMBO reports · 2021Article
- Review
- Role of Exosomes in the Progression, Diagnosis, and Treatment of Gliomas.Medical science monitor : international medical journal of experimental and clinical research · 2020Review
- Review
- Circulating biomarkers in patients with glioblastoma.British journal of cancer · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma multiforme (GBM) is the most aggressive and deadly primary brain cancer that arises from astrocytes and classified as grade IV. Recently, exosomes have been reported as an essential mediator in diverse cancer carcinogenesis and metastasis. However, their role in GBM is still unclear. In this study, we aimed to investigate whether blood exosomes can be potential clinical diagnostic markers for GBM.
methodsWe used a xenograft orthotopic mouse model to detect the differentially expressed genes in the brain and blood exosomes of original/recurrent GBM.
resultsWe found that recurrent GBM had stronger growth capacity and lethality than original GBM in the mouse model. A gene microarray of original tumors and blood exosomes from GBM orthotopic xenografts results showed that DNM3, p65 and CD117 expressions increased, whereas PTEN and p53 expressions decreased in both original tumors and blood exosomes. In the recurrent GBM tumor model, DNM3 and p65 showed increased expressions, whereas ST14 and p53 showed decreased expressions in tumor and blood exosomes of the recurrent GBM mouse model.
conclusionIn summary, we found that DNM3, p65 and p53 had a similar trend in brain and blood exosomes both for original and recurrent GBM, and could serve as potential clinical diagnostic markers for GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.